docetaxel,rucaparib,abiraterone,enzalutamide
pfizer,astellas,clovis oncology
['rucaparib', '#18 ', 'prostate', 'brca', 'crpc', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'docetaxel', 'triton3']
#gu23 abs#18 presents the interim results of the triton3 trial rucaparib significantly improved rpfs vs either docetaxel or abi/enza in brca/atm + mcrpc #prostatecancer. os trending favorably in brca+pts 
Medical Oncologist. Editor-in-chief: @ASCO Daily News; Presidential Endowed Chair, @HuntsmanCancer (NCI-CCC) @UUtah, FCOI https://t.co/qcdl19nxhM